Department of Clinical Medicine, Affiliated Hospital of Hangzhou Normal University, Hangzhou Normal University, Hangzhou, China.
Department of Immunology, Affiliated Hospital of Hangzhou Normal University, Hangzhou, China.
Pharmacol Res Perspect. 2024 Apr;12(2):e1177. doi: 10.1002/prp2.1177.
Diabetic cardiomyopathy (DCM) is a condition characterized by myocardial dysfunction that occurs in individuals with diabetes, in the absence of coronary artery disease, valve disease, and other conventional cardiovascular risk factors such as hypertension and dyslipidemia. It is considered a significant and consequential complication of diabetes in the field of cardiovascular medicine. The primary pathological manifestations include myocardial hypertrophy, myocardial fibrosis, and impaired ventricular function, which can lead to widespread myocardial necrosis. Ultimately, this can progress to the development of heart failure, arrhythmias, and cardiogenic shock, with severe cases even resulting in sudden cardiac death. Despite several decades of both fundamental and clinical research conducted globally, there are currently no specific targeted therapies available for DCM in clinical practice, and the incidence and mortality rates of heart failure remain persistently high. Thus, this article provides an overview of the current treatment modalities and novel techniques pertaining to DCM, aiming to offer valuable insights and support to researchers dedicated to investigating this complex condition.
糖尿病性心肌病（DCM）是一种以心肌功能障碍为特征的疾病，发生在患有糖尿病的个体中，而不存在冠状动脉疾病、瓣膜疾病和其他传统心血管危险因素，如高血压和血脂异常。它被认为是心血管医学领域中糖尿病的一个重要且有后果的并发症。主要的病理表现包括心肌肥厚、心肌纤维化和心室功能障碍，可导致广泛的心肌坏死。最终，这可能进展为心力衰竭、心律失常和心源性休克，严重情况下甚至导致心源性猝死。尽管全球进行了几十年的基础和临床研究，但目前在临床实践中尚无针对 DCM 的特定靶向治疗方法，心力衰竭的发病率和死亡率仍然居高不下。因此，本文概述了 DCM 的当前治疗方法和新技术，旨在为致力于研究这种复杂疾病的研究人员提供有价值的见解和支持。
